Best practice

Clinical trial participants retain access to investigational treatments

Novartis exemplifies a comprehensive approach to post-trial access to investigational medicines

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |